This study will evaluate the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus a placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
Who is the trial for? Women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer; confirmed biomarker PIK3CA mutation; they must have progressed during adjuvant treatment or within 12 months of completing endocrine therapy. Patients with bone only disease or history of type 1 or 2 diabetes are excluded.
New Zealand sites for this trial are: Auckland City Hospital, Waikato Hospital, Palmerston North Hospital and Christchurch Hospital. Please ask your doctor or medical team if you are interested in participating in this trial.
21 May 2021